Seeking Alpha

More on Celgene (CELG +5.1%) Q2: net profit $367M vs. $279M a year earlier; sales of Revlimid,...

More on Celgene (CELG +5.1%) Q2: net profit $367M vs. $279M a year earlier; sales of Revlimid, its multiple myeloma cancer drug, +17% to $934M. Increases FY EPS outlook to $4.80-$4.85 from previous forecast of $4.70-$4.80. Reiterates revenue guidance of around +15% to $5.4B-$5.6B. Consensus is for $4.80 and $5.45B.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|